Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838]

Affiliations

• ¹ Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia.
• ² Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Australia.
• ³ Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide, Australia; Department of Gynaecologic Oncology, Royal Adelaide Hospital, Adelaide, Australia.
• ⁴ Clinical and Health Sciences, University of South Australia, Australia.
• ⁵ Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia. Electronic address: shudong.wang@unisa.edu.au.